PMID- 27803793
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 7
IP  - 6
DP  - 2016 Nov
TI  - Sacubitril/valsartan in heart failure: latest evidence and place in therapy.
PG  - 278-290
AB  - Despite significant therapeutic advances, patients with chronic heart failure 
      (HF) remain at high risk for HF progression and death. Sacubitril/valsartan 
      (previously known as LCZ696) is a first-in-class medicine that contains a 
      neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor 
      blocker (valsartan). NEP is an endopeptidase that metabolizes different 
      vasoactive peptides including natriuretic peptides, bradykinin and Ang-II. In 
      consequence, its inhibition increases mainly the levels of both, natriuretic 
      peptides (promoting diuresis, natriuresis and vasodilatation) and Ang-II whose 
      effects are blocked by the angiotensin receptor blocker, valsartan (reducing 
      vasoconstriction and aldosterone release). Results from the 8442 patient 
      PARADIGM-HF study showed in patients with New York Heart Association (NYHA) class 
      II-IV and reduced ejection fraction treated with LCZ696 (versus enalapril), the 
      following benefits: reduction of the risk of death from cardiovascular causes by 
      20%; reduction of HF hospitalizations by 21%; reduction of the risk of all-cause 
      mortality by 16%. Overall there was a 20% risk reduction on the primary endpoint, 
      composite measure of cardiovascular (CV) death or time to first HF 
      hospitalization. PARADIGM-HF was stopped early after a median follow up of 27 
      months. Post hoc analyses of PARADIGM-HF as well as the place in therapy of 
      sacubitril/valsartan, including future directions, are included in the present 
      review.
FAU - Kaplinsky, Edgardo
AU  - Kaplinsky E
AD  - Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, Via Augusta 
      Av. 9-13, 08911 Badalona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161019
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC5076745
OTO - NOTNLM
OT  - LCZ696
OT  - PARADIGM-HF
OT  - heart failure
OT  - neprilysin
OT  - sacubitril/valsartan
COIS- The author declares that there is no conflict of interest.
EDAT- 2016/11/03 06:00
MHDA- 2016/11/03 06:01
PMCR- 2016/11/01
CRDT- 2016/11/03 06:00
PHST- 2016/11/03 06:00 [pubmed]
PHST- 2016/11/03 06:01 [medline]
PHST- 2016/11/03 06:00 [entrez]
PHST- 2016/11/01 00:00 [pmc-release]
AID - 10.1177_2040622316665350 [pii]
AID - 10.1177/2040622316665350 [doi]
PST - ppublish
SO  - Ther Adv Chronic Dis. 2016 Nov;7(6):278-290. doi: 10.1177/2040622316665350. Epub 
      2016 Oct 19.